Logo image of LAB

STANDARD BIOTOOLS INC (LAB) Stock Price, Forecast & Analysis

USA - NASDAQ:LAB - US34385P1084 - Common Stock

1.25 USD
+0.05 (+4.17%)
Last: 11/14/2025, 12:11:13 PM

LAB Key Statistics, Chart & Performance

Key Statistics
Market Cap477.50M
Revenue(TTM)128.83M
Net Income(TTM)-128.25M
Shares382.00M
Float371.75M
52 Week High2.25
52 Week Low0.92
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.34
PEN/A
Fwd PEN/A
Earnings (Next)02-24 2026-02-24/amc
IPO2011-02-10
Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences


LAB short term performance overview.The bars show the price performance of LAB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10

LAB long term performance overview.The bars show the price performance of LAB in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of LAB is 1.25 USD. In the past month the price decreased by -6.98%. In the past year, price decreased by -24.05%.

STANDARD BIOTOOLS INC / LAB Daily stock chart

LAB Latest News, Press Relases and Analysis

LAB Competitors/Peers

The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
TMO THERMO FISHER SCIENTIFIC INC 26.03 220.15B
DHR DANAHER CORP 28.85 159.26B
BRKRP BRUKER CORP - BRKR 6 3/8 09/01/28 163.31 49.55B
A AGILENT TECHNOLOGIES INC 27.12 41.91B
IQV IQVIA HOLDINGS INC 19.22 37.99B
MTD METTLER-TOLEDO INTERNATIONAL 33.89 29.21B
WAT WATERS CORP 30.23 22.85B
WST WEST PHARMACEUTICAL SERVICES 37.09 18.86B
ILMN ILLUMINA INC 27.83 18.65B
MEDP MEDPACE HOLDINGS INC 41.87 16.82B
TEM TEMPUS AI INC N/A 12.07B
RVTY REVVITY INC 19.29 10.73B

About LAB

Company Profile

LAB logo image Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. The company is headquartered in South San Francisco, California and currently employs 818 full-time employees. The company went IPO on 2011-02-10. The firm's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The firm works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. The company offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.

Company Info

STANDARD BIOTOOLS INC

2 Tower Place, Suite 2000

South San Francisco CALIFORNIA US

Employees: 818

LAB Company Website

LAB Investor Relations

Phone: 16502666000

STANDARD BIOTOOLS INC / LAB FAQ

What does STANDARD BIOTOOLS INC do?

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. The company is headquartered in South San Francisco, California and currently employs 818 full-time employees. The company went IPO on 2011-02-10. The firm's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The firm works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. The company offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.


What is the current price of LAB stock?

The current stock price of LAB is 1.25 USD. The price increased by 4.17% in the last trading session.


What is the dividend status of STANDARD BIOTOOLS INC?

LAB does not pay a dividend.


What is the ChartMill technical and fundamental rating of LAB stock?

LAB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


On which exchange is LAB stock listed?

LAB stock is listed on the Nasdaq exchange.


How is the market expecting LAB stock to perform?

7 analysts have analysed LAB and the average price target is 1.81 USD. This implies a price increase of 44.84% is expected in the next year compared to the current price of 1.25.


Can you provide the short interest for LAB stock?

The outstanding short interest for STANDARD BIOTOOLS INC (LAB) is 3.18% of its float.


LAB Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

LAB Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to LAB. LAB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LAB Financial Highlights

Over the last trailing twelve months LAB reported a non-GAAP Earnings per Share(EPS) of -0.34. The EPS increased by 52.11% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -23.77%
ROE -32.09%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-28.57%
Sales Q2Q%-56.52%
EPS 1Y (TTM)52.11%
Revenue 1Y (TTM)-17.37%

LAB Forecast & Estimates

7 analysts have analysed LAB and the average price target is 1.81 USD. This implies a price increase of 44.84% is expected in the next year compared to the current price of 1.25.

For the next year, analysts expect an EPS growth of 59.6% and a revenue growth -49.56% for LAB


Analysts
Analysts77.14
Price Target1.81 (44.8%)
EPS Next Y59.6%
Revenue Next Year-49.56%

LAB Ownership

Ownership
Inst Owners72.99%
Ins Owners2.54%
Short Float %3.18%
Short Ratio9.04